12ª ACTUALIZACIÓN en el TRATAMIENTO LEUCEMIA AGUDA 2023

del 5 al 7 OCT 2023



Dr. Juana Serrano
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

She has more than 15 years of research experience in different institutions in Spain and the USA: IMIBIC (Cordoba, Spain), CNIO (Madrid, Spain), CIC (Salamanca, Spain), CCHMC (Cincinnati, USA) and CNIC (Madrid, Spain).

In 2008 she completed her PhD at IMIBIC under the supervision of Dr Joaquín Sánchez and Dr Josefina Serrano. She developed a novel immunotherapy approach to enhance immune surveillance in acute myeloid leukemia.

At that time she became interested in identifying and targeting leukemia stem cells.

As she read and analyzed the topic of leukemia stem cell biology, she realized that successful targeting of leukemia stem cells would require a significant understanding of the physiology of normal hematopoietic stem cells and progenitors (HSC/Ps). To advance in this specific area, I moved to the laboratory of Dr. Jose Cancelas at the Cancer and Blood Diseases Institute of Cincinnati Children's Hospital Medical Center (CCHMC) in Cincinnati, Ohio for three years, from 2013 to 2016.

Under the supervision of Dr. Cancelas, she studied the signaling pathways that control HSC/P trafficking in vivo in response to inflammatory cues and circadian rhythm. She analyzed the role of TRAF6 in the TLR-dependent signaling pathway in HSC/P migration to lymph nodes. She also participated in the study of the role of TRAF6 in normal hematopoiesis and its function in myelodysplastic syndrome in collaboration with Dr. Daniel Starzcynowsky. Her expertise grew exponentially in animal manipulation in many types of transgenic and wild-type mice, learning the techniques of cell transplantation, limiting dilution assay and, most importantly, the value of cell number in hematopoiesis.

After returning to IMIBIC (2016-2018), she studied the impact of somatic mutations and fusion genes in acute leukemia. She was granted by Junta de Andalucía with a regional project to study DLBCL.

In 2017, she received the Seal of Excellence from the

European Commission for one of her projects based on the development of a novel ex vivo leukemic niche using 3D printing technology.

She is currently applying her expertise in the Experimental Hematology Lab at the Hospital Universitario Fundación Jiménez Díaz.

Her main goal is to unravel the bone marrow microenvironment to efficiently target LSC.

MD Anderson Cancer Center
Madrid • España